Drug Trial Radar · NCT04076462
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Aug 19, 2019
Primary completion
May 2, 2023
Study completion May 2, 2023
Sponsor
- Lead sponsor
- Camurus ABIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
Conditions
- Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot)Drug
Octreotide subcutaneous depot for monthly injections in acromegaly patients
Matching placeboDrug
Matching placebo for CAM2029
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Mean Insulin-like Growth Factor -1 (IGF-1) Levels ≤1 x Upper Limit of Normal (ULN) at Week 22/24Time frame: Week 22 and 24
Locations
63 sites in 10 countries. Site status is shown where the registry gives one.
UCLA Department of Medicine Division of Endocrinology
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
Prufen Clinical Research LLC
Miami, Florida
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University in St. Louis, School of Medicine
St Louis, Missouri
Palm Research Center
Las Vegas, Nevada
Columbia University Medical Center
New York, New York
University of Cincinnati
Cincinnati, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Allegheny Endocrinology Associates
Pittsburgh, Pennsylvania
Research Institute of Dallas
Dallas, Texas
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Frankfurt, Medizinische Klinik 1, Schwerpunkt Endokrinologie, Diabetologie, Ernährungsmedizin
Frankfurt, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
LMU Clinic of University of Munich, Medical Clinic and Polyclinic IV
Munich, Germany
Medicover Neuroendokrinologie
Munich, Germany
Medicover Oldenburg MVZ
Oldenburg, Germany
General Hospital of Athens "Laiko", Endocrinology University Clinic
Athens, Greece
Aretaeio University Hospital Endocrinology Department, Faculty of Diabetes and Metabolism
Athens, Greece
General Hospital of Thessaloniki "Ippokratio"
Thessaloniki, Greece
Military Healt Center, 2nd Department of Internal Medicine
Budapest, Hungary
SZTE ÁOK I.sz. Belgyógyászati Klinika
Szeged, Hungary
IRCCS Policlinico San Martino
Genova, Italy
Azienda Universitaria "Federico II"
Naples, Italy
Azienda Ospedaliera Padova, Department of Internal medicine
Padova, Italy
Policlinic Gemelli University Hospital IRCCS, Department of Endocrinology
Roma, Italy
AOUI Verona, Policlinic of GB Rossi
Verona, Italy
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
Krakow, Poland
Centrum Nowoczesnych Terapii "Dobry Lekarz"
Krakow, Poland
Amicare Sp. z o.o. Sp. K.
Lodz, Poland
Piekarskie Centrum Medyczne, Szpital Miejski
Piekary Śląskie, Poland
Interregional Clinical Diagnostic Center
Kazan', Russia
"Atlas" Medical Center
Moscow, Russia
Sechenov Moscow First State Medical University
Moscow, Russia
Vladimirsky Moscow Regional Research Clinical Institute
Moscow, Russia
Novosibirsk State Regional Clinical Hospital
Novosibirsk, Russia
Interregional Clinical Diagnostic Center
Ryazan, Russia
Saratov Regional Clinic Hospital
Saratov, Russia
University Hospital Complex A Coruña
A Coruña, Spain
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.